{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:52:36Z","timestamp":1792270356881,"version":"4.4.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lfs.2020.118189","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T23:19:40Z","timestamp":1596928780000},"page":"118189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects"],"prefix":"10.1016","volume":"378","author":[{"given":"Joyobrato","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajib","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar Kumar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishree","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baby","family":"Singha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitu","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2020.118189_bb0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006404","article-title":"Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: insights into parallel mechanisms of immune evasion","volume":"12","author":"Narasimhan","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1017\/S0031182016000147","article-title":"Cancer and life-history traits: lessons from host-parasite interactions","volume":"143","author":"Ujvari","year":"2016","journal-title":"Parasitology"},{"issue":"20","key":"10.1016\/j.lfs.2020.118189_bb0035","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2217\/nnm-2017-0102","article-title":"Nanoformulations of albendazole as effective anticancer and antiparasite agents","volume":"12","author":"Movahedi","year":"2017","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.lfs.2020.118189_bb0040","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1017\/S0031182000007290","article-title":"Albendazole: a review of anthelmintic efficacy and safety in humans","volume":"121 Suppl","author":"Horton","year":"2000","journal-title":"Parasitology."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0045","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0020-7519(01)00131-X","article-title":"The biochemical basis of anthelmintic action and resistance","volume":"31","author":"K\u00f6hler","year":"2001","journal-title":"Int. J. Parasitol."},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nor077","article-title":"Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme","volume":"13","author":"Bai","year":"2011","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41416-019-0681-5","article-title":"Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment","volume":"122","author":"Rushworth","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer","volume":"1871","author":"Nowak-Sliwinska","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0070","first-page":"168","article-title":"One drug for multiple targets: a computational perspective","volume":"60","author":"M\u00e9ndez-Lucio","year":"2016","journal-title":"J. Mex. Chem. Soc."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10637-017-0503-7","article-title":"Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas","volume":"36","author":"Kipper","year":"2018","journal-title":"Investig. New Drugs"},{"issue":"10","key":"10.1016\/j.lfs.2020.118189_bb0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"18","key":"10.1016\/j.lfs.2020.118189_bb0085","doi-asserted-by":"crossref","first-page":"9301","DOI":"10.1128\/JVI.01006-10","article-title":"Exploiting drug repositioning for discovery of a novel HIV combination therapy","volume":"84","author":"Clouser","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","article-title":"Drug repurposing for the treatment of glioblastoma multiforme","volume":"36","author":"Abbruzzese","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lfs.2020.118189_bb0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lfs.2020.118189_bb0100","doi-asserted-by":"crossref","first-page":"ed76","DOI":"10.3332\/ecancer.2018.ed76","article-title":"Does the oncology community have a rejection bias when it comes to repurposed drugs?","volume":"12","author":"Gyawali","year":"2018","journal-title":"ecancer"},{"key":"10.1016\/j.lfs.2020.118189_bb0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exppara.2015.06.007","article-title":"The helminth parasite proteome at the host-parasite interface - informing diagnosis and control","volume":"157","author":"van der Ree","year":"2015","journal-title":"Exp. Parasitol."},{"issue":"10066","key":"10.1016\/j.lfs.2020.118189_bb0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(16)32123-7","article-title":"Differential effect of mass deworming and targeted deworming for soil-transmitted helminth control in children: A systematic review and meta-analysis","volume":"389","author":"Clarke","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40249-019-0553-5","article-title":"Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions","volume":"8","author":"Bah","year":"2019","journal-title":"Infect. Dis. Poverty"},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","article-title":"Mode of action of benzimidazoles","volume":"6","author":"Lacey","year":"1990","journal-title":"Parasitol. Today"},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-91-4-582","article-title":"Mebendazole","volume":"91","author":"Keystone","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.lfs.2020.118189_bb0130","series-title":"World Health Organization Model List of Essential Medicines: 21st List 2019","author":"World Health Organization","year":"2019"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0135","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/CMR.14.1.150-164.2001","article-title":"Drug targets and mechanisms of resistance in the anaerobic protozoa","volume":"14","author":"Upcroft","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(14)70779-0","article-title":"Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial","volume":"14","author":"Garcia","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/41.2.145","article-title":"Albendazole","volume":"41","author":"Venkatesan","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijantimicag.2014.01.013","article-title":"Activities of fenbendazole in comparison with albendazole against Echinococcus multilocularis metacestodes in vitro and in a murine infection model","volume":"43","author":"K\u00fcster","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"10","key":"10.1016\/j.lfs.2020.118189_bb0155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/BF01138170","article-title":"The fumarate reductase system as a site of anthelmintic attack in Ascaris suum","volume":"4","author":"Barrowman","year":"1984","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006436","article-title":"Flubendazole as a macrofilaricide: history and background","volume":"13","author":"Geary","year":"2019","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14712\/18059694.2017.44","article-title":"Anthelmintic flubendazole and its potential use in anticancer therapy","volume":"60","author":"\u010c\u00e1\u0148ov\u00e1","year":"2017","journal-title":"Acta Med. (Hradec Kralove)"},{"key":"10.1016\/j.lfs.2020.118189_bb0170","first-page":"246","article-title":"Antifilarials and their mode of action","volume":"127","author":"Subrahmanyam","year":"1987","journal-title":"CIBA Found. Symp."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0175","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parint.2009.03.005","article-title":"Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces","volume":"58","author":"Cumino","year":"2009","journal-title":"Parasitol. Int."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/etm.2016.3992","article-title":"Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis","volume":"13","author":"Zhang","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/CAD.0b013e3283648c69","article-title":"Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines","volume":"24","author":"Kr\u00e1lov\u00e1","year":"2013","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.lfs.2020.118189_bb0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience."},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0195","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/cancers11091284","article-title":"Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature","volume":"11","author":"Guerini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0200","first-page":"285","article-title":"Flubendazole and mebendazole in the treatment of trichuriasis and other helminthiases","volume":"4","author":"Yangco","year":"1981","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40268-016-0142-z","article-title":"Safety of mebendazole use during lactation: a case series report","volume":"16","author":"Karra","year":"2016","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2018.50.1.1","article-title":"Albendazole and praziquantel: review and safety monitoring in Korea","volume":"50","author":"Hong","year":"2018","journal-title":"Infect. Chemother."},{"issue":"2\u20133","key":"10.1016\/j.lfs.2020.118189_bb0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0220","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.18632\/oncotarget.3436","article-title":"Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"issue":"8317","key":"10.1016\/j.lfs.2020.118189_bb0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(83)92753-8","article-title":"Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis","volume":"1","author":"Dominguez-Vazquez","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/00034983.1984.11811787","article-title":"Benzimidazoles in the treatment of trichuriasis: a review","volume":"78","author":"Rossignol","year":"1984","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0235","first-page":"185","article-title":"Flubendazole versus mebendazole in intestinal helminthic infections","volume":"39","author":"Feldmeier","year":"1982","journal-title":"Acta Trop."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4269\/ajtmh.1984.33.627","article-title":"Treatment of neurocysticercosis with flubendazole","volume":"33","author":"T\u00e9llez-Gir\u00f3n","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0245","first-page":"363","article-title":"Clinical trial of flubendazole on hookworm, Trichuris trichiura and Ascaris lumbricoides infections","volume":"11","author":"Bunnag","year":"1980","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"10.1016\/j.lfs.2020.118189_bb0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2119\/molmed.2017.00011","article-title":"Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors","volume":"23","author":"De Witt","year":"2017","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"42","key":"10.1016\/j.lfs.2020.118189_bb0260","doi-asserted-by":"crossref","first-page":"68571","DOI":"10.18632\/oncotarget.11851","article-title":"Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model","volume":"7","author":"Williamson","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0265","first-page":"2963","article-title":"Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo","volume":"8","author":"Mukhopadhyay","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yexcr.2018.05.006","article-title":"Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia","volume":"369","author":"He","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2020.118189_bb0275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bios.2016.04.081","article-title":"Silicon nanowire based biosensing platform for electrochemical sensing of Mebendazole drug activity on breast cancer cells","volume":"85","author":"Shashaani","year":"2016","journal-title":"Biosens. Bioelectron."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0280","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-007-0538-0","article-title":"Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice","volume":"61","author":"Martarelli","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0285","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.18632\/oncotarget.14673","article-title":"Anthelmintic mebendazole enhances cisplatin\u2019s effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-14-0755-T","article-title":"Repurposing the antihelmintic mebendazole as a hedgehog inhibitor","volume":"14","author":"Larsen","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0295","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/PAS.0b013e318243555b","article-title":"Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: An immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors","volume":"36","author":"Miettinen","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0300","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/ijms19051334","article-title":"ScFvs as allosteric inhibitors of VEGFR-2: novel tools to harness VEGF signaling","volume":"19","author":"Ballmer-Hofer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-009-0014-2","article-title":"Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors","volume":"97","author":"Blom","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.lfs.2020.118189_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discov."},{"issue":"12","key":"10.1016\/j.lfs.2020.118189_bb0315","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nrd2086","article-title":"Targeting the Hedgehog pathway in cancer","volume":"5","author":"Rubin","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.lfs.2020.118189_bb0320","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/cells7110208","article-title":"Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells","volume":"7","author":"Sari","year":"2018","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0325","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the Hedgehog signaling pathway in cancer: a comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosn. J. Basic. Med. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0330","doi-asserted-by":"crossref","first-page":"N15","DOI":"10.1227\/01.neu.0000460594.93803.cb","article-title":"Repurposing mebendazole for the treatment of medulloblastoma","volume":"76","author":"Bodhinayake","year":"2015","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0335","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11060-018-03009-7","article-title":"Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma","volume":"140","author":"Skibinski","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.lfs.2020.118189_bb0340","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.2147\/OTT.S143096","article-title":"Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism","volume":"10","author":"Markowitz","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"15","key":"10.1016\/j.lfs.2020.118189_bb0345","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","article-title":"Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model","volume":"21","author":"Bai","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lfs.2020.118189_bb0350","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","article-title":"Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer","volume":"139","author":"Nygren","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lfs.2020.118189_bb0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tiv.2019.06.010","article-title":"Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01)","volume":"60","author":"Pinto","year":"2019","journal-title":"Toxicol. in Vitro"},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0360","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.tiv.2015.08.007","article-title":"The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model","volume":"29","author":"Pinto","year":"2015","journal-title":"Toxicol. in Vitro"},{"issue":"7","key":"10.1016\/j.lfs.2020.118189_bb0365","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2020.118189_bb0370","doi-asserted-by":"crossref","unstructured":"Pinto LC, de F\u00e1tima Aquino Moreira-Nunes C, Soares BM, Burbano RMR, de Lemos JAR, Montenegro RC. Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol. in Vitro. 2017;43:87\u201391.","DOI":"10.1016\/j.tiv.2017.06.007"},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0375","first-page":"542","article-title":"Drugs in development for hepatocellular carcinoma","volume":"14","author":"Rimassa","year":"2018","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55666-x","article-title":"Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma","volume":"9","author":"Younis","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0385","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/08923973.2017.1320671","article-title":"The anticancer effect of mebendazole may be due to M1 monocyte\/macrophage activation via ERK1\/2 and TLR8-dependent inflammasome activation","volume":"39","author":"Blom","year":"2017","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0390","first-page":"1264","article-title":"Effect of the antiparasitic drug mebendazole on cholangiocarcinoma growth","volume":"45","author":"Sawanyawisuth","year":"2014","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"10.1016\/j.lfs.2020.118189_bb0395","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopha.2018.11.082","article-title":"Therapeutic potential of targeting the Wnt\/\u03b2-catenin signaling pathway in colorectal cancer","volume":"110","author":"Cheng","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118189_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.10.009","article-title":"Therapeutic targets in the Wnt signaling pathway: feasibility of targeting TNIK in colorectal cancer","volume":"156","author":"Masuda","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2020.118189_bb0405","article-title":"Comprehensive modeling and discovery of mebendazole as a novel TRAF2- and NCK-interacting kinase inhibitor","volume":"6","author":"Tan","year":"2016","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.lfs.2020.118189_bb0410","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2174\/1568026617666170104145640","article-title":"Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents","volume":"17","author":"Tangutur","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"13","key":"10.1016\/j.lfs.2020.118189_bb0415","first-page":"1201","article-title":"The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells","volume":"1","author":"Sasaki","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0420","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/ERC-19-0341","article-title":"Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer","volume":"27","author":"Williamson","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"issue":"56","key":"10.1016\/j.lfs.2020.118189_bb0425","doi-asserted-by":"crossref","first-page":"30805","DOI":"10.18632\/oncotarget.25713","article-title":"Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing","volume":"9","author":"Rubin","year":"2018","journal-title":"Oncotarget"},{"issue":"30","key":"10.1016\/j.lfs.2020.118189_bb0430","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/onc.2013.346","article-title":"The role of miR-150 in normal and malignant hematopoiesis","volume":"33","author":"He","year":"2014","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/j.lfs.2020.118189_bb0435","doi-asserted-by":"crossref","first-page":"18122","DOI":"10.1074\/jbc.RA119.010144","article-title":"DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis","volume":"294","author":"Hu","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0440","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/leu.2017.317","article-title":"Targeting acute myeloid leukemia by drug-induced c-MYB degradation","volume":"32","author":"Walf-Vorderw\u00fclbecke","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0445","doi-asserted-by":"crossref","first-page":"16775","DOI":"10.1038\/s41598-019-53290-3","article-title":"Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.lfs.2020.118189_bb0450","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrclinonc.2010.192","article-title":"Breast cancer: challenges, controversies, breakthroughs","volume":"7","author":"Hutchinson","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0455","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2018.08.046","article-title":"Mebendazole potentiates radiation therapy in triple-negative breast cancer","volume":"103","author":"Zhang","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lfs.2020.118189_bb0460","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jpba.2017.05.024","article-title":"Bioelectrical impedimetric sensor for single cell analysis based on nanoroughened quartz substrate; suitable for cancer therapeutic purposes","volume":"142","author":"Gharooni","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0465","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.13593","article-title":"Epidemiology of prostate cancer in Asian countries","volume":"25","author":"Kimura","year":"2018","journal-title":"Int. J. Urol."},{"issue":"10","key":"10.1016\/j.lfs.2020.118189_bb0470","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.3390\/ijms20102530","article-title":"Biological rationale for targeting MEK\/ERK pathways in anti-cancer therapy and to potentiate tumour responses to radiation","volume":"20","author":"Marampon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.lfs.2020.118189_bb0475","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0480","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/ijms20051194","article-title":"Nuclear ERK: mechanism of translocation, substrates, and role in cancer","volume":"20","author":"Maik-Rachline","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0485","doi-asserted-by":"crossref","first-page":"12576","DOI":"10.18632\/oncotarget.14990","article-title":"The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma","volume":"8","author":"Simbulan-Rosenthal","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0490","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","article-title":"Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells","volume":"6","author":"Doudican","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CAD.0b013e32835a43f1","article-title":"XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts","volume":"24","author":"Doudican","year":"2013","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0500","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2019.05.024","article-title":"Palliative radiation therapy for head and neck cancers","volume":"105","author":"Grewal","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0505","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hed.24733","article-title":"Reirradiation of head and neck cancer: long-term disease control and toxicity","volume":"39","author":"Bots","year":"2017","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0510","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.4158\/EP10390.CR","article-title":"Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma","volume":"17","author":"Dobrosotskaya","year":"2011","journal-title":"Endocr. Pract."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0515","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","article-title":"Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer","volume":"53","author":"Nygren","year":"2014","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0520","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12282-019-01027-5","article-title":"18F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer","volume":"27","author":"Liu","year":"2020","journal-title":"Breast Cancer"},{"issue":"11","key":"10.1016\/j.lfs.2020.118189_bb0525","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/molecules24112152","article-title":"Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells","volume":"24","author":"Mrkvov\u00e1","year":"2019","journal-title":"Molecules"},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.118189_bb0530","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11010-016-2927-3","article-title":"Albendazole inhibits HIF-1\u03b1-dependent glycolysis and VEGF expression in non-small cell lung cancer cells","volume":"428","author":"Zhou","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0535","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/07357900802210752","article-title":"Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole","volume":"27","author":"Pourgholami","year":"2009","journal-title":"Cancer Investig."},{"key":"10.1016\/j.lfs.2020.118189_bb0540","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcp.2018.11.003","article-title":"Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3\/ROS\/p38 MAPK\/TTP axis-mediated TNF-\u03b1 upregulation","volume":"162","author":"Wang","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118189_bb0545","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2076579","article-title":"Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC) cells","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"42","key":"10.1016\/j.lfs.2020.118189_bb0550","doi-asserted-by":"crossref","first-page":"71512","DOI":"10.18632\/oncotarget.17292","article-title":"Repurposing albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer","volume":"8","author":"Ghasemi","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0555","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1208\/s12249-018-1169-y","article-title":"Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer","volume":"19","author":"Priotti","year":"2018","journal-title":"AAPS Pharm. Sci. Tech."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0560","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.cdd.4401913","article-title":"p53 and disease: when the guardian angel fails","volume":"13","author":"Royds","year":"2006","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0565","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ph9020025","article-title":"Chemical variations on the p53 reactivation theme","volume":"9","author":"Ribeiro","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.lfs.2020.118189_bb0570","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2020.118189_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","article-title":"Modulating ROS to overcome multidrug resistance in cancer","volume":"41","author":"Cui","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.lfs.2020.118189_bb0580","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.redox.2016.09.013","article-title":"Albendazole as a promising molecule for tumor control","volume":"10","author":"Castro","year":"2016","journal-title":"Redox Biol."},{"issue":"10","key":"10.1016\/j.lfs.2020.118189_bb0585","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/07357907.2016.1245317","article-title":"Hypoxia: a double-edged sword in cancer therapy","volume":"34","author":"Manoochehri Khoshinani","year":"2016","journal-title":"Cancer Investig."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0590","first-page":"469","article-title":"Cancer stem cells and hypoxia-inducible factors (review)","volume":"53","author":"Tong","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0595","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2020.118189_bb0600","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1748-717X-6-160","article-title":"Albendazole sensitizes cancer cells to ionizing radiation","volume":"6","author":"Patel","year":"2011","journal-title":"Radiat. Oncol."},{"issue":"32","key":"10.1016\/j.lfs.2020.118189_bb0605","doi-asserted-by":"crossref","first-page":"26648","DOI":"10.1021\/acsami.7b05292","article-title":"Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis","volume":"9","author":"Tang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.lfs.2020.118189_bb0610","first-page":"3791","article-title":"Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole","volume":"29","author":"Chu","year":"2009","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0615","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","article-title":"Albendazole: A potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice","volume":"12","author":"Pourgholami","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0620","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1933719111398142","article-title":"Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice","volume":"18","author":"Choi","year":"2011","journal-title":"Reprod. Sci."},{"issue":"5A","key":"10.1016\/j.lfs.2020.118189_bb0625","first-page":"2775","article-title":"Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells","volume":"28","author":"Pourgholami","year":"2008","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0630","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1517\/13543776.2016.1146252","article-title":"Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011\u20132015)","volume":"26","author":"Ban","year":"2016","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.lfs.2020.118189_bb0635","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2407-10-143","article-title":"Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole","volume":"10","author":"Pourgholami","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2020.118189_bb0640","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12951-015-0082-8","article-title":"Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model","volume":"13","author":"Noorani","year":"2015","journal-title":"J. Nanobiotechnol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0645","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CAD.0000000000000914","article-title":"Albendazole suppresses cell proliferation and migration and induces apoptosis in human pancreatic cancer cells","volume":"31","author":"Chen","year":"2020","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0650","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","article-title":"In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole","volume":"165","author":"Pourgholami","year":"2001","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0655","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00280-004-0927-6","article-title":"Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis","volume":"55","author":"Pourgholami","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.118189_bb0660","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijpharm.2016.09.056","article-title":"Dual effect of F-actin targeted carrier combined with antimitotic drug on aggressive colorectal cancer cytoskeleton: allying dissimilar cell cytoskeleton disrupting mechanisms","volume":"513","author":"Taranejoo","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.lfs.2020.118189_bb0665","first-page":"3659","article-title":"Complexation of albendazole with hydroxypropyl-\u03b2-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice","volume":"32","author":"Ehteda","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2020.118189_bb0670","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-13-86","article-title":"Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice","volume":"13","author":"Ehteda","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0675","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bcp.2007.05.006","article-title":"Epothilone-paclitaxel resistant leukemic cells CEM\/dEpoB300 are sensitive to albendazole: involvement of apoptotic pathways","volume":"74","author":"Khalilzadeh","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0680","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-016-0207-3","article-title":"Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease","volume":"17","author":"Burton","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0685","first-page":"185","article-title":"Wnt signaling pathway in development and cancer","volume":"69","author":"Taciak","year":"2018","journal-title":"J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0690","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Anastas","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0695","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000055351","article-title":"Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers\/high incidence of neutropenia","volume":"61","author":"Morris","year":"2001","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0700","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-009-1157-8","article-title":"Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer","volume":"65","author":"Pourgholami","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"23","key":"10.1016\/j.lfs.2020.118189_bb0705","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0710","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0715","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118189_bb0720","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fphar.2019.00600","article-title":"Carbonyl reduction of flubendazole in the human liver: strict stereospecificity, sex difference, low risk of drug interactions","volume":"10","author":"Kub\u00ed\u010dek","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118189_bb0725","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2017.10.020","article-title":"Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer","volume":"412","author":"Kim","year":"2018","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.lfs.2020.118189_bb0730","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.lfs.2020.118189_bb0735","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","article-title":"Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype","volume":"68","author":"Gerratana","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.lfs.2020.118189_bb0740","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1039\/C5MB00466G","article-title":"Systems biology-based discovery of a potential Atg4B agonist (flubendazole) that induces autophagy in breast cancer","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol. BioSyst."},{"issue":"2","key":"10.1016\/j.lfs.2020.118189_bb0745","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/jphp.12503","article-title":"Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro","volume":"68","author":"Kr\u00e1lov\u00e1","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2020.118189_bb0750","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1074\/jbc.REV119.007759","article-title":"Cell adhesion in cancer: beyond the migration of single cells","volume":"295","author":"Janiszewska","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.lfs.2020.118189_bb0755","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1871520618666171213141911","article-title":"The effect of flubendazole on adhesion and migration in SW480 and SW620 colon cancer cells","volume":"18","author":"Hanu\u0161ov\u00e1","year":"2018","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.lfs.2020.118189_bb0760","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Guy GP Jr. Stemming the rising incidence of melanoma: calling prevention to action. J. Natl. Cancer Inst.. 2015;108(1).","DOI":"10.1093\/jnci\/djv381"},{"key":"10.1016\/j.lfs.2020.118189_bb0765","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.tiv.2017.10.025","article-title":"Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells","volume":"46","author":"\u010c\u00e1\u0148ov\u00e1","year":"2018","journal-title":"Toxicol. in Vitro"},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0770","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118189_bb0775","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2020.118189_bb0780","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2019.05.026","article-title":"The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation","volume":"459","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.lfs.2020.118189_bb0785","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14737140.2017.1285230","article-title":"Overview and recent advances in the treatment of neuroblastoma","volume":"17","author":"Whittle","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.lfs.2020.118189_bb0790","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/srep08202","article-title":"Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen","volume":"5","author":"Michaelis","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.lfs.2020.118189_bb0795","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.devcel.2019.04.010","article-title":"Epithelial-Mesenchymal plasticity in cancer progression and metastasis","volume":"49","author":"Lu","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.lfs.2020.118189_bb0800","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cbi.2018.07.026","article-title":"Flubendazole and mebendazole impair migration and epithelial to mesenchymal transition in oral cell lines","volume":"293","author":"Kralova","year":"2018","journal-title":"Chem. Biol. Interact."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520309413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520309413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T15:19:06Z","timestamp":1751210346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520309413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":160,"alternative-id":["S0024320520309413"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118189","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118189"}}